Using Elispot assay, we found that the ratio of IFN-γ-producing CD8+NKG2D+ cells was increased up to 4 folds within tumour masses (Fig. 4a) and up to 5 folds in the spleens (Fig. 4b) isolated from mice treated with MV-Edm and CD8+NKG2D+, compared to those receiving CD8+NKG2D+ alone. This evidence concerns the gene CD8A and neoplasm.